Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
PLRX 
Pliant Therapeutics Inc (PLRX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: PLRX (1-star) is a SELL. SELL since 5 days. Profits (-8.81%). Updated daily EoD!
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
13 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $2.96
1 Year Target Price $2.96
| 1 | Strong Buy |
| 1 | Buy |
| 11 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -47.84% | Avg. Invested days 19 | Today’s Advisory SELL |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 100.68M USD | Price to earnings Ratio - | 1Y Target Price 2.96 |
Price to earnings Ratio - | 1Y Target Price 2.96 | ||
Volume (30-day avg) 13 | Beta 1.43 | 52 Weeks Range 1.10 - 16.10 | Updated Date 08/29/2025 |
52 Weeks Range 1.10 - 16.10 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.38 |
Earnings Date
Report Date 2025-08-07 | When - | Estimate -0.6595 | Actual -0.71 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -35.07% | Return on Equity (TTM) -67.55% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -101820428 | Price to Sales(TTM) 3071.82 |
Enterprise Value -101820428 | Price to Sales(TTM) 3071.82 | ||
Enterprise Value to Revenue 1376.69 | Enterprise Value to EBITDA -2.54 | Shares Outstanding 61388200 | Shares Floating 55572854 |
Shares Outstanding 61388200 | Shares Floating 55572854 | ||
Percent Insiders 3.04 | Percent Institutions 85.69 |
Upturn AI SWOT
Pliant Therapeutics Inc
Company Overview
History and Background
Pliant Therapeutics, Inc. was founded in 2016 and is a clinical stage biotechnology company focused on discovering and developing novel therapeutics for fibrotic diseases. The company is headquartered in South San Francisco, California.
Core Business Areas
- Fibrosis Therapies: Development of therapeutics targeting fibrosis in various organs, including idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC).
Leadership and Structure
Dr. Bernard Coulie serves as Chief Executive Officer. The company has a board of directors comprised of experienced individuals from the biotechnology and pharmaceutical industries.
Top Products and Market Share
Key Offerings
- Bexotegrast (PLN-74809): An oral, small-molecule selective inhibitor of u03b1vu03b26 integrin, currently in Phase 2b clinical trials for IPF. Bexotegrast is also in Phase 2a for PSC. Competitors include Boehringer Ingelheim and Roche with their approved IPF drugs, Ofev and Esbriet, respectively. Market share data for Bexotegrast is currently unavailable as it is still in clinical development. Revenue from this product is $0 as it is still in trial.
Market Dynamics
Industry Overview
The biopharmaceutical industry focusing on fibrotic diseases is growing, driven by unmet medical needs and aging populations. There's an increasing emphasis on developing targeted therapies with improved efficacy and safety profiles.
Positioning
Pliant Therapeutics aims to be a leader in the fibrosis therapeutics market with its integrin-targeting approach. Its selective u03b1vu03b26 integrin inhibitor is designed to offer a differentiated mechanism of action compared to existing therapies.
Total Addressable Market (TAM)
The global fibrosis market is estimated to be in the tens of billions of dollars. Pliant's position depends on clinical trial outcomes and successful commercialization of Bexotegrast. If successful, they would capture a significant portion of the market.
Upturn SWOT Analysis
Strengths
- Novel therapeutic approach targeting integrins
- Strong intellectual property portfolio
- Experienced management team
- Promising clinical trial results for Bexotegrast
Weaknesses
- Reliance on a single lead product candidate (Bexotegrast)
- Clinical trial risks and uncertainties
- Limited commercialization experience
- Significant capital requirements for drug development
Opportunities
- Expansion into additional fibrotic disease indications
- Potential for strategic partnerships and collaborations
- Accelerated regulatory pathways for orphan drug designation
- Growing prevalence of fibrotic diseases
Threats
- Competition from established pharmaceutical companies
- Unfavorable clinical trial results
- Regulatory hurdles and delays
- Patent challenges
Competitors and Market Share
Key Competitors
- BI (Boehringer Ingelheim), RHHBY (Roche Holding AG)
- GILD (Gilead Sciences Inc.)
Competitive Landscape
Pliant Therapeutics has a competitive advantage with their integrin-targeting approach but faces competition from established players with approved therapies.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is primarily driven by preclinical and clinical development progress, as well as partnerships and financings.
Future Projections: Future growth depends on the success of Bexotegrast in clinical trials and potential expansion into new indications. Analyst estimates can be found on financial websites like Yahoo Finance or Bloomberg.
Recent Initiatives: Recent initiatives include advancing Bexotegrast through clinical trials for IPF and PSC, exploring new therapeutic targets, and seeking strategic partnerships.
Summary
Pliant Therapeutics is a clinical-stage biotech company with a novel approach to treating fibrotic diseases. While the company's reliance on Bexotegrast carries risk, promising clinical trial results and a strong IP position offer significant potential. Key watchpoints include competition from established players and the need for successful future trials.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Pliant Therapeutics' corporate website
- SEC filings
- Financial news websites (e.g., Yahoo Finance, Bloomberg)
- Analyst reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market share data is estimated and subject to change. Clinical trial outcomes are uncertain and could affect Pliant Therapeutics' future performance.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Pliant Therapeutics Inc
Exchange NASDAQ | Headquaters South San Francisco, CA, United States | ||
IPO Launch date 2020-06-03 | President, CEO & Director Dr. Bernard Coulie M.B.A., M.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 171 | Website https://pliantrx.com |
Full time employees 171 | Website https://pliantrx.com | ||
Pliant Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases. The company's lead candidate includes bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which has completed phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325, a phase 1-ready program for treatment of the muscular dystrophies, including duchenne muscular dystrophy. Pliant Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.